Psoriatic Arthritis Treatment Denied: Navigating Dermatology and Rheumatology Coverage

Psoriatic arthritis (PsA) is an inflammatory arthritis affecting up to 30% of people with psoriasis, causing joint pain, stiffness, swelling, and structural joint damage. Treatment requires biologics that address both the skin and joint components of disease. But because PsA sits at the intersection of dermatology and rheumatology, it creates unique insurance coverage challenges — including benefit assignment disputes, step therapy contradictions, and denial of treatments covered for one specialty but not the other.

The Core PsA Insurance Challenge

PsA biologics are FDA-approved for both psoriasis and psoriatic arthritis. The same biologic may be:

• Covered under the pharmacy benefit when prescribed by a dermatologist for psoriasis
• Covered under the medical benefit when infused in a rheumatology office
• Subject to different step therapy requirements depending on which specialty is prescribing

This creates a situation where a patient treated by both a dermatologist and a rheumatologist may face duplicate Prior Authorization Denied: How to Appeal" class="auto-link">prior authorizations with different criteria — and denial under one benefit while being approved under another.

CASPAR Criteria: Proving the PsA Diagnosis

The CASPAR (Classification of Psoriatic Arthritis) criteria are the standard diagnostic framework for PsA. A diagnosis requires inflammatory articular disease (joint, spine, or entheseal) plus 3 or more points from:

• Current psoriasis (2 points); history of psoriasis (1 point); family history of psoriasis (1 point)
• Psoriatic nail dystrophy (1 point)
• Negative rheumatoid factor (1 point)
• Current dactylitis (1 point); history of dactylitis (1 point)
• Juxtaarticular new bone formation on X-ray (1 point)

Document CASPAR criteria clearly in your dermatologist's or rheumatologist's notes. Without a documented PsA diagnosis, the joint indication for biologic treatment may not be recognized by insurance reviewers.

ACR and EULAR Guidelines as Appeal Evidence

ACR (American College of Rheumatology): Publishes PsA treatment guidelines recommending biologics (TNF inhibitors, IL-17 inhibitors, IL-12/23 and IL-23 inhibitors, JAK inhibitors, T-cell costimulation inhibitor abatacept) for patients with active PsA who have failed conventional DMARDs (typically methotrexate).

EULAR (European Alliance of Associations for Rheumatology): Publishes international PsA management recommendations that align with ACR guidelines and are recognized by international review panels.

Cite both ACR and EULAR guidelines when appealing PsA biologic denials, particularly when step therapy through DMARDs (methotrexate, sulfasalazine, leflunomide) is required but has been completed.

Medical Benefit vs. Pharmacy Benefit Disputes

For infused biologics (Remicade/infliximab, Simponi Aria, Orencia IV):

• Must go through the medical benefit, not pharmacy benefit
• PA must be submitted to the medical benefit department
• Infusion facility PA may also be required separately

For self-injectable biologics (Humira, Enbrel, Cosentyx, Taltz, Tremfya, Skyrizi, Rinvoq, Otezla):

• Typically covered under pharmacy benefit
• May have different formulary tiers and step therapy requirements under pharmacy vs. medical benefit

If you're being denied because the claim was submitted to the wrong benefit, this is a billing/coordination issue, not a true coverage denial. Request resubmission to the correct benefit.

Step Therapy Across Dermatology and Rheumatology

A common frustration: the rheumatologist prescribes a biologic and the insurer requires failure on a TNF inhibitor first — but the dermatologist previously tried that same TNF inhibitor for psoriasis and it failed. Document that the failed biologic step for psoriasis satisfies the joint step therapy requirement, since PsA biologics are the same agents used across both indications.

Your appeal letter should:

• Identify the prior TNF inhibitor trial (drug name, dates, doses, reason for failure)
• Explicitly state that this same biologic addresses both PsA and plaque psoriasis
• Note that re-challenging with a failed biologic is not clinically appropriate

When Dermatologist and Rheumatologist Co-Prescribe

If your dermatologist and rheumatologist are both involved in care and both recommend the same biologic, include letters from both treating physicians in your appeal. Dual-specialty medical necessity letters are highly persuasive to insurance reviewers.

Documenting Joint Disease Severity

For joint-related medical necessity, include:

• HAQ-DI (Health Assessment Questionnaire Disability Index) score
• SJC (swollen joint count) and TJC (tender joint count) — 66/68 joint count
• CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) values
• Imaging: X-ray, MRI, or ultrasound showing periarticular erosions, enthesitis, or dactylitis
• DAS28-CRP or DAPSA disease activity scores

Fight Back With ClaimBack

ClaimBack's psoriatic arthritis appeal tools combine CASPAR criteria documentation, ACR/EULAR guideline citations, and benefit assignment guidance to address the unique challenges of PsA coverage disputes.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal